Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2005
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Michelle A Lowes, Francesca Chamian, Maria Veronica Abello, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Acta Dermato-Venereologica|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 TrialsDiamant Thaçi, Luis Puig, Sei-Ichiro Motegi, et al.
Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.
The New England Journal of Medicine|October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisMark Lebwohl, Bruce Strober, Alan Menter, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2005
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Michelle A Lowes, Francesca Chamian, Maria Veronica Abello, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Acta Dermato-Venereologica|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 TrialsDiamant Thaçi, Luis Puig, Sei-Ichiro Motegi, et al.
Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.
The New England Journal of Medicine|October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisMark Lebwohl, Bruce Strober, Alan Menter, et al.
Pageof 14